Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)

Benign Prostatic Hyperplasia Clinical Trial

— REZUM  

Official title:

Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01912339
• Other study ID #: 2105-001
• Status: Completed
• Phase: N/A
• Start date: July 2013
• Est. completion date: October 17, 2016

Study information

• Verified date: April 2020
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of the Rezūm System and assess its effect on urinary symptoms secondary to benign prostatic hyperplasia (BPH).

Description:

This study is a prospective, controlled, randomized single blind clinical trial of subjects with benign prostatic hyperplasia, which will allow for an interim analysis for sample size adjustment. Subjects first will be randomized in a 2:1 proportion in favor of the Treatment arm. Subjects in the Control arm will be allowed to crossover to have the Rezūm treatment after the 3-month follow-up examination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 197
• Est. completion date: October 17, 2016
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Male subjects > 50 years of age who have symptomatic BPH.

2. International Prostate Symptom Score (IPSS) score = 13.

3. Peak urinary flow rate (Qmax): = 5ml/sec to = 15 ml/sec with minimum voided volume of = 125 ml.

4. Post-void residual (PVR) =250 ml.

5. Prostate volume > 30 and = 80 gm.

Exclusion Criteria:

1. History of clinically significant congestive heart failure (i.e. NYHA Class III and IV).

2. History of diabetes not controlled by a stable dose of medication over the past three months. Patients with a Hemoglobin A1c that is <8.0% are allowed.

3. History of significant respiratory disease where hospitalization for the disease is required.

4. History of immunosuppressive conditions (e.g., AIDS, post-transplant).

5. Cardiac arrhythmias that are not controlled by medication or medical device.

6. An episode of unstable angina pectoris, a myocardial infarction, transient ischemic attack, or a cerebrovascular accident within the past six months.

7. Any significant medical history that would pose an unreasonable risk or make the subject unsuitable for the study.

8. Presence of a penile implant or stent(s) in the urethra or prostate.

9. Any prior invasive prostate intervention (e.g., radio frequency (RF) ablation, balloon, microwave, or laser) or other surgical interventions of the prostate.

10. Currently enrolled in any other pre-approval investigational study in the USA (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.)).

11. History of confirmed malignancy or cancer of prostate or bladder, however, high grade PIN is acceptable.

12. History of cancer in non-genitourinary system that is not considered cured (except basal cell or squamous cell carcinoma of the skin). A potential participant is considered cured if there has been no evidence of cancer within five years of randomization.

13. Previous pelvic irradiation or radical pelvic surgery.

14. Diagnosed with active Lyme Disease (borreliosis).

15. PSA > 10 ng/ml unless prostate cancer is ruled out by biopsy. If PSA is > 2.5 ng/ml and = 10 ng/ml with free PSA <25%, prostate cancer for the subject must be/had been ruled out through a negative biopsy prior to enrollment.

16. Has undergone prostate biopsy within 60 days prior to treatment date or has an imminent need for surgery.

17. Previous rectal surgery (other than hemorrhoidectomy) or known history of rectal disease.

18. Active urinary tract infection by culture within 7 days of treatment or two documented independent urinary tract infections of any type in the past 6 months.

19. Verified bacterial prostatitis within last 12 months documented by culture or non-bacterial prostatitis within the last 5 years.

20. Active or history of epididymitis within the past 3 months.

21. Neurogenic bladder, sphincter abnormalities, or poor detrusor muscle function.

22. Diagnosed or suspected primary neurologic conditions such as multiple sclerosis or Parkinson's disease or other neurological diseases known to affect bladder function, sphincter function or poor detrusor muscle function.

23. Urethral strictures, bladder neck contracture, unusual anatomy or muscle spasms that would prevent the introduction and use of the device.

24. Diagnosed bladder, urethral or ureteral stones or active stone passage in the past 6 months. Stones that are known to be in the kidney and have been stable for a period exceeding 3 months are permissible.

25. Post-void residual (PVR) > 250 ml.

26. Diagnosed or suspected bleeding disorder, or coagulopathies.

27. Use of antiplatelet or anticoagulant medication except low dose aspirin (=81 mg/day) within 10 days prior to treatment.

28. Visible hematuria with subject urine sample without a known contributing factor.

29. Subject interested in maintaining fertility.

30. Use of beta-blockers, anticonvulsants, and antispasmodics where the dose is not stable. (Stable dose is defined as having the same medication and dose in the last six months).

31. At the time of baseline assessment, in the absence of a qualifying exception, subjects who are using or have used the following medications, and are unable or unwilling to discontinue using these medications for the prescribed washout period:

1. Use of antihistamines within 1 week of treatment unless there is documented evidence of stable dosing for last 6 months (no dose changes).

2. Use of the alpha blockers for BPH and anticholinergics or cholinergics (except for topical anti cholinergic eye drops), or within 4 weeks of baseline assessment.

3. Use of Type II, 5-alpha reductase inhibitor (e.g., finasteride (Proscar, Propecia) within 3 months of baseline assessment.

4. Use of a dual 5-alpha reductase inhibitor (e.g., dutasteride (Avodart)) within 6 months of baseline assessment.

5. Use of estrogen, drug-producing androgen suppression, or anabolic steroids within 3 months of baseline assessment.

6. Use of daily dose PD5 Inhibitors (e.g.Viagra, Levitra or Cialis) within 4 weeks of baseline assessment.

32. Subjects who have had an incidence of spontaneous urinary retention either treated with indwelling transurethral catheter or suprapubic catheter six months prior to baseline. A provoked episode now resolved is still admissible.

33. Compromised renal function defined as serum creatinine > 2.0 mg/dl.

34. Inability to provide a legally effective Informed Consent Form (ICF) and/or comply with all the required follow-up requirements.

35. Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affect the ability to complete the study quality of life questionnaires.

Related Conditions & MeSH terms

• Benign Prostatic Hyperplasia
• Hyperplasia
• Lower Urinary Tract Symptom
• Lower Urinary Tract Symptoms
• Prostatic Hyperplasia

Intervention

Device:
• Rezum System
The Rezum System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland. A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum. A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices. Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death.

Procedure:
• Rigid Cystoscopy
Endoscopy of the urinary bladder via the urethra.

Locations

Country	Name	City	State
United States	South Florida Medical Research	Aventura	Florida
United States	Texas Urology	Carrollton	Texas
United States	The Urology Group	Cincinnati	Ohio
United States	Cleveland Clinic	Cleveland	Ohio
United States	UT Southwestern	Dallas	Texas
United States	Urology Associates of Denver	Denver	Colorado
United States	Carolina Urologic Research Center	Myrtle Beach	South Carolina
United States	Manhattan Medical Research	New York	New York
United States	Mayo Clinic	Rochester	Minnesota
United States	Jean Brown Research	Salt Lake City	Utah
United States	Urology of San Antonio	San Antonio	Texas
United States	Southern Illinois University	Springfield	Illinois
United States	Chesapeake Urology	Towson	Maryland
United States	Arizona Institute of Urology	Tucson	Arizona
United States	Metro Urology	Woodbury	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Boston Scientific Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy: Change From Baseline in the International Prostate Symptom Score (IPSS) at 3 Month Follow-Up	Comparison of the change in BPH symptoms as measured by IPSS change between the Treatment and Control arm at 3 months post-treatment. The IPSS is a well-validated, highly reliable and responsive American Urological Association symptom score (AUASS) assessment to identify the severity of BPH Symptoms. The first seven questions of the IPSS Questionnaire address frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying and urgency each on a scale of 0 to 5. The total score, summed across the seven items measured, ranges from 0 (no symptoms) to 35 (most severe symptoms).	3 Month Follow-up Visit
Primary	Safety: Device Related Serious Complications	This safety endpoint will be to demonstrate that the composite observed rate of post-procedure device related serious complications in the Treatment Arm are is less than or equal to 12% at 3 months.; Composite device related serious complications for this endpoint are 1) De Novo (new) severe urinary retention lasting more than 21 consecutive days post treatment, 2) Device related formation of fistula between the rectum and urethra, and 3) device perforation of the rectum or GI tract. Twelve percent was a pre-specified performance goal for the safety endpoint.	3 Months
Secondary	Responders at 3 Months	Number of subjects with a greater than or equal to 30% improvement (reduction) in the International Prostate Symptom score (IPSS) at 3 months compared to baseline.	3 Months
Secondary	Responders at 6 Months	Number of subjects with a greater than or equal to 30% improvement (reduction) in the International Prostate Symptom score (IPSS) at 6 months compared to baseline.	6 Months
Secondary	Responders at 12 Months	Number of subjects with a greater than or equal to 30% improvement (reduction) in the International Prostate Symptom score (IPSS) at 12 months compared to baseline.	12 Months

External Links

•   The Journal of Urology Vol. 195, 1529-1538, May 2016